Literature DB >> 19070402

Gallium(III) complexes of 2-pyridineformamide thiosemicarbazones: cytotoxic activity against malignant glioblastoma.

Isolda C Mendes1, Marcela A Soares, Raquel G Dos Santos, Carlos Pinheiro, Heloisa Beraldo.   

Abstract

The gallium(III) complexes [Ga(2Am4DH)(2)]NO(3) (1), [Ga(2Am4Me)(2)]NO(3) (2) and [Ga(2Am4Et)(2)]NO(3) (3) were prepared with 2-pyridineformamide thiosemicarbazone (H2Am4DH) and its N(4)-methyl (H2Am4Me) and N(4)-ethyl (H2Am4Et) derivatives. The thiosemicarbazones were cytotoxic against malignant RT2 glioblastoma cells (expressing p53 protein) with IC(50) values in the 7.3-360 microM range, and against malignant T98 glioblastoma cells (expressing mutant p53 protein) with IC(50) values in the 3.6-143 microM range. Coordination to gallium strongly increased the cytotoxic potential in complexes 2 and 3, which showed IC(50) values in the 0.81-9.57 microM range against RT2 cells and in the 3.6-11.30 microM range against T98 cells, and were 20-fold more potent than cisplatin. All thiosemicarbazones and gallium complexes were able to induce cell death by apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19070402     DOI: 10.1016/j.ejmech.2008.11.006

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  13 in total

1.  Gallium compound GaQ(3) -induced Ca(2+) signalling triggers p53-dependent and -independent apoptosis in cancer cells.

Authors:  Rajan Gogna; Esha Madan; Bernhard Keppler; Uttam Pati
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Gallium-containing anticancer compounds.

Authors:  Christopher R Chitambar
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

3.  Biological study of the effect of water soluble [N-(2-hydroxybenzyl)-L-aspartato] gallium complexes on breast carcinoma and fibrosarcoma cells.

Authors:  Ahmed Mohsen; Charles Saby; Philippe Collery; Gilane Mohamed Sabry; Rasha Elsherif Hassan; Abdelfattah Badawi; Pierre Jeannesson; Didier Desmaële; Hamid Morjani
Journal:  J Biol Inorg Chem       Date:  2016-08-02       Impact factor: 3.358

4.  Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands.

Authors:  Beatriz Gallego; Milena R Kaluđerović; Harish Kommera; Reinhard Paschke; Evamarie Hey-Hawkins; Torsten W Remmerbach; Goran N Kaluđerović; Santiago Gómez-Ruiz
Journal:  Invest New Drugs       Date:  2010-05-15       Impact factor: 3.850

5.  Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study.

Authors:  Éva A Enyedy; Michael F Primik; Christian R Kowol; Vladimir B Arion; Tamás Kiss; Bernhard K Keppler
Journal:  Dalton Trans       Date:  2011-04-27       Impact factor: 4.390

Review 6.  Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.

Authors:  Christopher R Chitambar; William E Antholine
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

Review 7.  Medical applications and toxicities of gallium compounds.

Authors:  Christopher R Chitambar
Journal:  Int J Environ Res Public Health       Date:  2010-05-10       Impact factor: 3.390

8.  Synthesis, crystal structure and antiproliferative mechanisms of gallium(iii) complexes with benzoylpyridine thiosemicarbazones.

Authors:  Jinxu Qi; Taichen Liu; Wei Zhao; Xinhua Zheng; Yihong Wang
Journal:  RSC Adv       Date:  2020-05-18       Impact factor: 4.036

9.  Cu(ii), Ga(iii) and In(iii) complexes of 2-acetylpyridine N(4)-phenylthiosemicarbazone: synthesis, spectral characterization and biological activities.

Authors:  Yu-Ting Wang; Yan Fang; Meng Zhao; Ming-Xue Li; Yu-Mei Ji; Qiu-Xia Han
Journal:  Medchemcomm       Date:  2017-10-09       Impact factor: 3.597

Review 10.  Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes.

Authors:  Katarzyna Gałczyńska; Zuzanna Drulis-Kawa; Michał Arabski
Journal:  Molecules       Date:  2020-07-31       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.